Match tier Listed
Presence Current · Arkansas
Last published 2020
Sources OpenAlex · ORCID
Refreshed 2026-10-03

Amy D Greenway

Role not yet determined Is this you? Add your title

UAMS

Also affiliated: University of Arkansas Medical Center (2009–2017); Arkansas Children's Nutrition Center (2008–2010)

7 h-index 20 pubs 1,071 cited

Research Areas

Biomedical Subjects

  • Humans
  • Castleman Disease
  • Antineoplastic Agents
  • Immunotherapy, Adoptive
  • Cell Proliferation
  • Practice Guidelines as Topic
  • Herpesvirus 8, Human
  • Female
  • Killer Cells, Natural
  • Male
  • Multiple Myeloma
  • Blotting, Western
  • Animals
  • Interleukin-6 Inhibitors
  • Lipid Metabolism

Links

Lab Website

Metrics

  • h-index: 7
  • Publications: 20
  • Citations: 1,071

Selected Publications

  • International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease (2020)
    Blood Advances 218 citations DOI OpenAlex
  • Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization (2018)
    Blood 2 citations DOI OpenAlex
  • Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma (2018)
    Blood 1 citation DOI OpenAlex
  • Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center (2018)
    Blood 1 citation DOI OpenAlex
  • International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease (2018)
    Blood 418 citations DOI OpenAlex
  • The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells (2017)
    Blood 1 citation DOI OpenAlex
  • Treatment of Idiopathic Castleman Disease (2017)
    Hematology/Oncology Clinics of North America 72 citations DOI OpenAlex
  • Myeloma-Derived Exosomes and Soluble Factors Suppress Natural Killer Cell Function (2016)
    Blood 7 citations DOI OpenAlex
  • Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma (2015)
    Blood DOI OpenAlex
  • Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity (2013)
    Blood DOI OpenAlex
  • Myeloma Can Modulate Expanded Natural Killer Cell Function Through Multiple Mechanisms (2012)
    Blood DOI OpenAlex
  • Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order (2012)
    Blood 3 citations DOI OpenAlex
  • Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients (2012)
    Blood 6 citations DOI OpenAlex
  • Highly activated and expanded natural killer cells for multiple myeloma immunotherapy (2012)
    Haematologica 107 citations DOI OpenAlex
  • Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma (2011)
    Blood DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

100 Collaborators 37 Institutions 8 Countries

Top Collaborators

View profile →
View profile →